Online inquiry

IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14358MR)

This product GTTS-WQ14358MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ANGPT2&VEGFA gene. The antibody can be applied in Diabetic macular edema, Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens; Humanized
RefSeq NM_001118887.2; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 285; 7422
UniProt ID O15123; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ14358MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4537MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-936558
GTTS-WQ10897MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MABp1
GTTS-WQ3112MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA APN311
GTTS-WQ6414MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CT-011
GTTS-WQ1670MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACZ885
GTTS-WQ6628MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ1543MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACE-031
GTTS-WQ15879MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA XMT-1536
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW